Fireman B.V. (IFRX) Stock Price, Quote & News

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 3641 508 180

Website: www.inflarx.de

Address:

Winzerlaer Str. 2, Jena, Germany

NYBomba Jun. 5 at 3:13 AM

$IFRX - what’s all this talk about one dollar, why stop there, why not 50 cents or better yet one penny… some of you are turning into dumb money, you’re consumed with watching the tape and become fueled by constant assumptions, the facts are clear, IFRX is loaded with cash, partnership is near, pipeline is evolving, thats why you bought the stock… you think you got it bad, what about the investors who gave IFRX 150 million to make it happen … have some conviction or just sell and move on…

0 · Reply

EdV3 Jun. 4 at 8:03 PM

$IFRX 🥲

1 · Reply

Yoyo35 Jun. 4 at 7:04 PM

$IFRX @EdV3 I should have followed your lead and not checked the stock today🙂

0 · Reply

Holten7575 Jun. 4 at 5:31 PM

$IFRX well thats enough for me--- be back when we reach 1.00 to buy some more--wont hang around to watch the crooks drop it more

0 · Reply

Jdorkshire Jun. 4 at 4:25 PM

$IFRX Here comes the 2$ flush along with a volume surge.

1 · Reply

cielo1 Jun. 4 at 1:06 PM

$IFRX are we ready yet? Pre July the 4th!

0 · Reply

JerzeyDevil Jun. 4 at 12:49 PM

$IFRX 😂

1 · Reply

Yoyo35 Jun. 4 at 12:24 PM

$IFRX Nice pre market

0 · Reply

bsyd02 Jun. 4 at 11:59 AM

$IFRX damn sub two :/

1 · Reply

TheDragonsClaw Jun. 4 at 10:52 AM

$STFS $WOLF $IFRX __

0 · Reply

InflaRx upgraded to Strong Buy from Outperform at Raymond James

2026-05-11T18:30:06.000Z - 24 days ago

InflaRx price target raised to $8 from $6 at H.C. Wainwright

May 8, 2026, 8:30 AM EDT - 27 days ago

InflaRx Transcript: Investor update

May 8, 2026, 8:30 AM EDT - 27 days ago

InflaRx Press release: Investor update

May 8, 2026, 8:30 AM EDT - 27 days ago

InflaRx Slides: Investor update

May 8, 2026, 8:15 AM EDT - 27 days ago

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

2026-05-07T03:51:29.000Z - 4 weeks ago

InflaRx to develop izicopan in AAV

May 6, 2026, 8:30 AM EDT - 4 weeks ago

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

May 6, 2026, 8:25 AM EDT - 4 weeks ago

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

2026-05-04T12:09:26.000Z - 4 weeks ago

InflaRx announces new izicopan pre-clinical data

May 4, 2026, 7:30 AM EDT - 4 weeks ago

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

May 1, 2026, 7:30 AM EDT - 4 weeks ago

InflaRx to Report First Quarter 2026 Results on May 7, 2026

Apr 28, 2026, 7:30 AM EDT - 5 weeks ago

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

2026-04-24T11:41:38.000Z - 5 weeks ago

InflaRx assumed with an Outperform at Oppenheimer

2026-04-09T11:54:44.000Z - 2 months ago

InflaRx announces new izicopan in vitro findings

Apr 9, 2026, 7:30 AM EDT - 2 months ago

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

Mar 31, 2026, 7:30 AM EDT - 2 months ago

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

2026-03-30T12:10:23.000Z - 2 months ago

InflaRx presents vilobelimab data

Mar 30, 2026, 7:30 AM EDT - 2 months ago

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

2026-03-20T11:20:14.000Z - 2 months ago

InflaRx price target lowered to $14 from $22 at Guggenheim

Mar 19, 2026, 9:30 AM EDT - 2 months ago

InflaRx Annual report: Q4 2025

Mar 19, 2026, 9:30 AM EDT - 2 months ago

InflaRx Earnings release: Q4 2025

2026-03-19T11:35:54.000Z - 2 months ago

InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year

Mar 19, 2026, 7:30 AM EDT - 2 months ago

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Mar 18, 2026, 7:30 AM EDT - 2 months ago

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

Mar 13, 2026, 5:00 PM EDT - 2 months ago

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 12, 2026, 7:30 AM EDT - 3 months ago

InflaRx to Report Full Year 2025 Results on March 19, 2026

Mar 9, 2026, 9:20 AM EDT - 3 months ago

InflaRx Transcript: Leerink Global Healthcare Conference 2026

Feb 26, 2026, 7:30 AM EST - 3 months ago

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

Feb 25, 2026, 8:40 AM EST - 3 months ago

InflaRx Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 11:30 AM EST - 4 months ago

InflaRx Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 29, 2026, 7:30 AM EST - 4 months ago

InflaRx Announces Participation in February Investor Conferences

2026-01-08T13:21:00.000Z - 5 months ago

InflaRx to prioritize izicopan as lead asset, reduces workforce by 30%

Jan 8, 2026, 8:00 AM EST - 5 months ago

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

2025-12-30T12:40:39.000Z - 5 months ago

InflaRx outlines data analyses of Phase 3 study for vilobelimab in PG

Dec 30, 2025, 7:30 AM EST - 5 months ago

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

2025-12-11T12:35:44.000Z - 6 months ago

InflaRx announces international nonproprietary name of “izicopan” for INF904

Dec 11, 2025, 7:30 AM EST - 6 months ago

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

2025-12-03T11:53:16.000Z - 6 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink

2025-12-03T11:16:16.000Z - 6 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink

Nov 11, 2025, 2:30 PM EST - 7 months ago

InflaRx Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-11T11:20:32.000Z - 7 months ago

InflaRx price target raised to $8 from $3 at Cantor Fitzgerald

2025-11-11T11:16:27.000Z - 7 months ago

InflaRx price target raised to $9 from $2 at Raymond James

2025-11-11T11:15:24.000Z - 7 months ago

InflaRx price target raised to $7 from $3 at Oppenheimer

2025-11-10T21:11:57.000Z - 7 months ago

InflaRx price target raised to $24 from $3 at Lucid Capital

Nov 10, 2025, 4:00 PM EST - 7 months ago

InflaRx Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 7 months ago

InflaRx Transcript: Status Update

Nov 10, 2025, 8:00 AM EST - 7 months ago

InflaRx Press release: Status Update

Nov 10, 2025, 8:00 AM EST - 7 months ago

InflaRx Slides: Status Update

Nov 10, 2025, 7:30 AM EST - 7 months ago

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

Nov 7, 2025, 4:05 PM EST - 7 months ago

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Oct 21, 2025, 7:20 AM EDT - 8 months ago

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Sep 4, 2025, 9:10 AM EDT - 9 months ago

InflaRx Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 7:30 AM EDT - 10 months ago

InflaRx Announces Participation in September Investor Conferences

Aug 7, 2025, 7:30 AM EDT - 10 months ago

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:00 AM EDT - 10 months ago

InflaRx Earnings release: Q2 2025

Jul 31, 2025, 7:30 AM EDT - 11 months ago

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

Jun 4, 2025, 7:35 AM EDT - 1 year ago

InflaRx Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 1:30 AM EDT - 1 year ago

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 22, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Upcoming Investor Conferences

May 7, 2025, 9:30 AM EDT - 1 year ago

InflaRx Earnings release: Q1 2025

May 7, 2025, 7:30 AM EDT - 1 year ago

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025

Mar 20, 2025, 9:30 AM EDT - 1 year ago

InflaRx Earnings release: Q4 2024

Mar 20, 2025, 9:30 AM EDT - 1 year ago

InflaRx Annual report: Q4 2024

Mar 20, 2025, 7:30 AM EDT - 1 year ago

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Mar 7, 2025, 8:00 AM EST - 1 year ago

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 28, 2025, 9:00 AM EST - 1 year ago

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 25, 2025, 7:30 AM EST - 1 year ago

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Feb 18, 2025, 4:01 PM EST - 1 year ago

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 9:45 PM EST - 1 year ago

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 4:01 PM EST - 1 year ago

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Jan 23, 2025, 7:30 AM EST - 1 year ago

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Jan 15, 2025, 12:30 PM EST - 1 year ago

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Dec 20, 2024, 7:30 AM EST - 1 year ago

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Dec 4, 2024, 2:30 PM EST - 1 year ago

InflaRx Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 15, 2024, 7:51 AM EST - 1 year ago

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Nov 11, 2024, 11:00 AM EST - 1 year ago

InflaRx Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 8, 2024, 9:30 AM EST - 1 year ago

InflaRx Earnings release: Q3 2024

Nov 8, 2024, 7:30 AM EST - 1 year ago

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 25, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

Sep 18, 2024, 9:45 AM EDT - 1 year ago

InflaRx Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 3, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Aug 27, 2024, 7:30 AM EDT - 1 year ago

InflaRx Announces Participation in September Investor Events

Aug 8, 2024, 9:30 AM EDT - 1 year ago

InflaRx Earnings release: Q2 2024

Aug 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 2 years ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

Jun 24, 2024, 8:02 AM EDT - 2 years ago

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

Jun 5, 2024, 12:00 PM EDT - 2 years ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904

May 21, 2024, 2:30 PM EDT - 2 years ago

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 8, 2024, 7:30 AM EDT - 2 years ago

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 7:00 AM EDT - 2 years ago

InflaRx Earnings release: Q1 2024

Apr 24, 2024, 7:30 AM EDT - 2 years ago

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

NYBomba Jun. 5 at 3:13 AM

0 · Reply

EdV3 Jun. 4 at 8:03 PM

$IFRX 🥲

1 · Reply

Yoyo35 Jun. 4 at 7:04 PM

$IFRX @EdV3 I should have followed your lead and not checked the stock today🙂

0 · Reply

Holten7575 Jun. 4 at 5:31 PM

$IFRX well thats enough for me--- be back when we reach 1.00 to buy some more--wont hang around to watch the crooks drop it more

0 · Reply

Jdorkshire Jun. 4 at 4:25 PM

$IFRX Here comes the 2$ flush along with a volume surge.

1 · Reply

cielo1 Jun. 4 at 1:06 PM

$IFRX are we ready yet? Pre July the 4th!

0 · Reply

JerzeyDevil Jun. 4 at 12:49 PM

$IFRX 😂

1 · Reply

Yoyo35 Jun. 4 at 12:24 PM

$IFRX Nice pre market

0 · Reply

bsyd02 Jun. 4 at 11:59 AM

$IFRX damn sub two :/

1 · Reply

TheDragonsClaw Jun. 4 at 10:52 AM

$STFS $WOLF $IFRX __

0 · Reply

Yoyo35 Jun. 4 at 9:53 AM

$IFRX Do you think the upcoming big tech IPOs are attracting retail investors’ capital? A lot of biotech stocks have been in the red for over a week now, while many tech stocks continue to significantly outperform the market.

1 · Reply

Holten7575 Jun. 4 at 9:23 AM

$IFRX

0 · Reply

Holten7575 Jun. 4 at 9:07 AM

$IFRX who buys and sells 1 and 11 shares… so stupid

0 · Reply

RKLBupupup Jun. 3 at 11:38 PM

$IFRX somebody wants in cheap

1 · Reply

mconnell Jun. 3 at 11:03 PM

$IFRX defending the price feels like

0 · Reply

morgueana Jun. 3 at 10:40 PM

$IFRX Buy back shares at these low prices with further pending partnership funding on top of large cash position? Should stop shorts cold and show confidence in your company. We have money now-- Do something proactive management. An inside buy every decade or so wouldn't hurt either.

4 · Reply

JerzeyDevil Jun. 3 at 9:28 PM

$IFRX Believe me now?

1 · Reply

EdV3 Jun. 3 at 8:15 PM

$IFRX Ehhhhh.....I abhor downside gaps.... For my own sanity I'm not gonna look tomorrow Too soon to add in size (again) imo....r/r favors the 1.60 fill at this juncture. That's when you back up the truck. Praying I'm wrong

1 · Reply

Holten7575 Jun. 3 at 7:29 PM

$IFRX must be some way to report this intentional walking

2 · Reply

Holten7575 Jun. 3 at 7:28 PM

$IFRX they will put it nicely at 1.99 --pricks

0 · Reply

DaveyScatino Jun. 3 at 6:42 PM

$IFRX bio really seems to be struggling lately. If it goes under 2 I will probably buy more. Would rather see a huge partnership announcement

0 · Reply

Holten7575 Jun. 3 at 5:59 PM

$IFRX Charts dont mean shyt when it is purposely walked down

0 · Reply

Market Cap	148.92M
Revenue (ttm)	30,000.00
Net Income (ttm)	-51.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-172,100.01%
Debt to Equity Ratio	0.00

Volume	1,272,100
Avg Vol	1,995,056
Day's Range	N/A - N/A
Shares Out	72.29M
Stochastic %K	2%
Beta	2.42
Analysts	Strong Sell
Price Target	$8.00